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SUMMARY
Acute lymphoblastic leukemia (ALL) is associated with significant morbidity and mortality, 
necessitating further improvements in diagnosis and therapy. Targeted therapies directed against 
chromatin regulators are emerging as promising approaches in preclinical studies and early clinical 
trials. Here, we demonstrate an oncogenic role for the protein lysine methyltransferase SETDB2 in 
leukemia pathogenesis. It is overexpressed in pre-BCR+ ALL and required for their maintenance 
in vitro and in vivo. SETDB2 expression is maintained as a direct target gene of the chimeric 
transcription factor E2A-PBX1 in a subset of ALL and suppresses expression of the cell-cycle 
inhibitor CDKN2C through histone H3K9 tri-methylation, thus establishing an oncogenic pathway 
subordinate to E2A-PBX1 that silences a major tumor suppressor in ALL. In contrast, SETDB2 
was relatively dispensable for normal hematopoietic stem and progenitor cell proliferation. 
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SETDB2 knockdown enhances sensitivity to kinase and chromatin inhibitors, providing a 
mechanistic rationale for targeting SETDB2 therapeutically in ALL.
Graphical abstract
In Brief: Lin et al. report that the protein lysine methyltransferase SETDB2 is a direct target of 
chimeric transcription factor E2A-PBX1 and required for pathogenesis in B cell precursor 
leukemia. SETDB2 suppresses expression of the cell-cycle inhibitor CDKN2C, establishing an 
oncogenic pathway that silences a major tumor suppressor in acute leukemia.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is associated with significant morbidity and mortality 
in adults and children, despite ongoing improvements in diagnosis and therapy. ALLs are 
sub-categorized based on their karyotype, cell type, and immunophenotype, and many are 
associated with fusion proteins that serve as driving oncogenic mutations (Armstrong and 
Look, 2005; Pui and Evans, 2006). One of these fusion proteins is E2A-PBX1, which fuses 
the transcription factor E2A with the homeobox gene PBX1 to create a chimeric 
transcription factor involved in a phenotypically and genetically distinctive subtype of ALL 
(Borowitz et al., 1993; Nourse et al., 1990) associated with an intermediate clinical risk 
(Moorman et al., 2007; Pui et al., 2004). Despite its key role in leukemia pathogenesis, E2A-
PBX1 has not yet proven to be a “druggable” transcription factor for therapeutic targeting. A 
potential strategy that circumvents this obstacle is to target the products of essential 
downstream genes. Several genes encoding pre-B cell receptor components are directly 
regulated by E2A-PBX1 to sustain the expression of a functional pre-B cell receptor 
complex (Geng et al., 2015), and targeting the pre-B cell receptor signaling pathway with 
kinase inhibitors shows promising efficacy in preclinical studies of E2A-PBX1+ ALL 
(Duque-Afonso et al., 2016; Geng et al., 2015). However, this approach is likely to be 
limited, since inhibition of kinase signaling pathways is generally associated with 
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development of resistance and short-lived clinical response (Logue and Morrison, 2012; 
Sakamoto et al., 2015).
An alternative approach is to target chromatin modifier enzymes (epigenetic regulators), 
whose function may be required by or cooperate with chimeric transcription factors in 
leukemia development (Dawson and Kouzarides, 2012). Many leukemias harbor mutations 
in epigenetic factors (Cancer Genome Atlas Research Network et al., 2013), and epigenetic 
regulators may be aberrantly expressed or recruited to oncoprotein complexes to drive 
leukemia development (Bernt et al., 2011; Gilan et al., 2016; Zhu et al., 2016). Thus, 
inhibition of epigenetic regulators is an emerging therapeutic approach for antagonizing 
oncogenic transcription programs, including those driven by chimeric transcription factors, 
and several epigenetic therapies have been advanced into clinical trials (Cai et al., 2015). 
Furthermore, preclinical studies show that combination therapy targeting epigenetic factors 
has greater efficacy and less toxicity (Gilan et al., 2016). However, there is little 
understanding of the epigenetic factors that may functionally contribute to ALL 
pathogenesis.
To identify critical epigenetic regulators in ALL, we used high-throughput genomic 
approaches, which identified SETDB2, a histone H3K9 tri-methyltransferase, as a major 
regulator of leukemogenesis downstream of E2A-PBX1. Our studies provide basic 
mechanistic insight into the epigenetic role of SETDB2 in leukemia pathogenesis and 
implicate it as a promising therapeutic target.
RESULTS
SETDB2 Is an Epigenetic Target Gene of E2A-PBX1 in preB-ALL
To identify potential downstream effectors in E2A-PBX1-transformed pre-BCR+ leukemia, a 
differential expression screen was conducted using human E2A-PBX1+ cell lines (RCH-
ACV and 697) depleted of E2A-PBX1 by short hairpin RNAs (shRNAs) coupled with high-
throughput RNA sequencing (RNA-seq) (Figures S1A–S1D). The overall quality of RNA-
seq data was assured by sample-wise clustering based on global transcriptomic expression 
(Figure S2A). This identified 364 and 323 genes that were significantly upregulated and 
downregulated, respectively, in both cell lines (Figure S2B). Collectively, these 687 
differentially expressed genes were enriched in gene ontology (GO) terms “lymphocyte 
differentiation,” “regulation cell death,” and “apoptosis,” consistent with the observed 
phenotypes in RCH-ACV cells depleted of E2A-PBX1 (Figure S2C). In addition, previously 
reported genetic targets associated with E2A-PBX1+ preB-ALL, such as WNT16 (Diakos et 
al., 2014; McWhirter et al., 1999) and NOTCH2 (Feldman et al., 2000), were also captured 
in this screen. Taken together, these data demonstrated the robustness and sensitivity of the 
high-throughput screen for the transcriptional program subordinate to E2A-PBX1 in pre-
BCR+ ALL cells.
Since epigenetic regulators play important roles in leukemia initiation and development, the 
dataset was interrogated for epigenetic factors whose expression was directly or indirectly 
dependent on E2A-PBX1. Notably, SETDB2, a member of the protein lysine 
methyltransferase (PKMT) family coding for an H3K9 tri-methyltransferase, was 
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downregulated with high significance in two E2A-PBX1+ cell lines (697 and RCH-ACV) 
following depletion of E2A-PBX1 (Figure 1A). Western blot analysis also confirmed that 
shRNA-mediated E2A-PBX1 knockdown resulted in decreased levels of SETDB2 in these 
two cell lines (Figure 1B). In addition, PRDM8, which codes for an H3K9me2 
methyltransferase, was also downregulated in both cell lines but only reached statistical 
significance in 697 cells. Therefore, we reasoned that H3K9 methylation, typically 
associated with repressive chromatin states, may be a potential critical epigenetic mark in 
E2A-PBX1-mediated oncogenic transformation. In support of this hypothesis, SETDB2 was 
observed to be significantly overexpressed in E2A-PBX1+ patients compared with 
mononuclear control cells (Figure 1C) (Haferlach et al., 2010). Furthermore, chromatin 
immunoprecipitation (ChIP)-PCR analysis demonstrated that E2A-PBX1 occupied the 
SETDB2 promoter (Figure 1D), consistent with ChIP sequencing (ChIP-seq) data (Geng et 
al., 2015) and suggesting that SETDB2 is likely an E2A-PBX1 binding target in primary 
patient ALL (Figure S2D). In support of this, E2A-PBX1 strongly activated the proximal 
SETDB2 promoter as measured by reporter assay (Figure S2E). Taken together, these data 
demonstrate that SETDB2 is a candidate epigenetic target in E2A-PBX1-induced preB-
ALL.
SETDB2 Is Critical for Growth and Maintenance of Human E2A-PBX1+ preB-ALL
To functionally delineate the role of SETDB2 in E2A-PBX1+ preB-ALL, its potential 
oncogenic requirement was assessed using in vitro and in vivo transformation model 
systems. SETDB2 depletion by shRNA knockdown in three E2A-PBX1+ human leukemia 
cell lines significantly reduced and impaired in vitro growth in liquid culture or colony 
formation in methylcellulose medium, strong indicators of their dependency on SETDB2 
(Figures 2A–2E). The in vivo requirement of SETDB2 was assessed in non-obese diabetic-
severe combined immunodeficiency (NOD-SCID) mice transplanted with either control or 
SETDB2 depleted cells. Mice transplanted with two different dosages of SETDB2-depleted 
cells survived about 50% longer than control mice (Figure 2F). Although leukemia 
eventually developed in mice transplanted with SETDB2-depleted cells, this was caused by 
cells that had escaped SETDB2 knockdown by unknown mechanisms (Figures 2F and 2G), 
further supporting the essential requirement for SETDB2. To complement results from the 
knockdown studies, a CRISPR-Cas9 approach (Heckl et al., 2014) was used to inactivate 
SETDB2 in E2A-PBX1+ cells (Figures 2H and 2I; Figure S3A). E2A-PBX1+ cells 
transduced with SETDB2 small guide RNAs (sgRNAs) (GFP+ cells) showed a 40% growth 
reduction in liquid culture compared to control cells (Figure 2J; Figure S3C), which matched 
the percentage of SETDB2 deletion measured by Sanger sequencing of GFP+ individual 
cells (Figure S3B). Taken together, multiple experimental approaches demonstrate that E2A-
PBX1+ leukemia cells are strongly dependent on SETDB2 for leukemia maintenance.
Human Hematopoietic Stem and Progenitor Cells Are Less Dependent on SETDB2
In direct comparison with primary leukemia samples, SETDB2 expression levels were 
significantly lower in normal hematopoietic stem and progenitor cells (cord blood and adult 
bone marrow CD34+ cells) (Figure 3A). In addition, analysis of several public RNA-seq 
datasets also showed that SETDB2 expression levels are lower in normal hematopoietic stem 
and progenitor cells (HSPCs) than primary leukemia cells (Figure 3B). The functional 
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contributions of SETDB2 were examined by shRNA knockdown in cord blood and adult 
bone marrow CD34+ cells (Figures 3C and 3F) using colony-forming assays, which showed 
only slight reduction in colony-forming efficiency between control or SETDB2 knockdown 
HSPCs (Figures 3D, 3E, 3G, and 3H), in contrast to the substantial growth inhibition 
mediated by SETDB2 shRNAs in leukemia cells (Figures 2C–2E). Furthermore, SETDB2 
was observed to have very low expression (on average, 3.8 reads per kilobase of transcript 
per million mapped reads [RPKM]) in more than 50 different normal tissues (Figure S4A). 
To gain more insight into the function of SETDB2 in leukemia pathogenesis, it was 
overexpressed in cord blood CD34+ cells. No significant differences were observed in the 
colony-forming abilities of SETDB2-expressing versus control CD34+ cells (Figures S4B 
and S4C), and its overexpression did not transform mouse HSPCs (data not shown). Thus, 
SETDB2 alone cannot transform progenitor cells. Together, these findings suggest that 
SETDB2 has low impact on normal HSPC function and is selectively important for leukemia 
cells, supporting its further evaluation as a therapeutic target.
SETDB2 Mediates Oncogenic Effects in E2A-PBX1+ ALL through Suppression of CDKN2C 
and Cell-Cycle Perturbation
To elucidate the oncogenic mechanism of SETDB2 in leukemia maintenance, global levels 
of H3K9me3, a silencing histone mark, were assessed by western blot and ChIP-seq after 
SETDB2 depletion in RCH-ACV cells. The results showed that global levels of H3K9me3 
were not impacted by SETDB2 depletion (Figures 4A–4C), suggesting that the oncogenic 
mechanism of SETDB2 is likely mediated by more restricted effects on select target genes. 
Analysis of the transcriptomic dataset by gene set enrichment analysis (GSEA) showed that 
the expression of multiple cell-cycle-related gene sets was significantly enriched in 
SETDB2-depleted RCH-ACV versus control cells (Figure 4D; Figure S5A), implicating that 
cell-cycle-related genes are potential SETDB2 downstream targets. To identify potential 
direct targets of SETDB2, an integrative analysis of ChIP-seq and transcriptomic data was 
performed that identified a subset of genes (n = 27) whose H3K9me3 levels were reduced 
concomitantly with increased transcript levels following SETDB2 depletion (Figure 4E; 
Figure S5B). Notably, the gene for the cell-cycle inhibitor CDKN2C was one of the potential 
SETDB2 targets that met the selection criteria (Figure 4F).
Given that multiple cell-cycle gene sets were associated with SETDB2 depletion, CDKN2C 
was investigated for its role in SETDB2-mediated E2A-PBX1+ leukemia development. 
ChIP-qPCR assay detected the binding of endogenous SETDB2 on the CDKN2C locus, 
confirming that CDKN2C is a direct target of SETDB2 (Figure 5A). ChIP-qPCR assays also 
confirmed the ChIP-seq data that shRNA-mediated SETDB2 depletion resulted in the 
reduction of H3K9me3 levels at the CDKN2C locus (Figure 5B). Conversely, exogenous 
overexpression of a SETDB2-GFP fusion protein increased the level of H3K9me3 on the 
CDKN2C locus (Figure 5C), which correlated with increased chromatin occupancy of 
SETDB2-GFP at CDKN2C (Figure 5D). In addition, depletion of SETDB2 or E2A-PBX1 
substantially upregulated CDKN2C transcript levels (Figures 5E and 5F), demonstrating a 
strong dependency of CDKN2C repression on upstream E2A-PBX1-mediated signaling.
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Given the role of CDKN2C in cell-cycle regulation, the cell-cycle state was evaluated in 
leukemia cells following CDKN2C perturbations. Although there was no significant change 
in cell-cycle status following CDKN2C knockdown (Figures 5G and 5H), likely due to its 
low basal level of expression, exogenous overexpression of CDKN2C in RCH-ACV cells 
significantly induced growth arrest and apoptosis (Figures 5I and 5J), resulting in reduced 
cell proliferation (Figure 5K). These results phenocopy the loss of SETDB2 (Figures 5G and 
5H) or E2A-PBX1 (Figures S5C and S5D) and indicate that SETDB2 serves a crucial role in 
regulating proliferation in E2A-PBX1+ ALL cells through direct regulation of CDKN2C. 
Furthermore, knockdown of CDKN2C significantly rescued the growth deficiency in E2A-
PBX1- or SETDB2-depleted RCH-ACV cells, demonstrating that CDKN2C is an important 
downstream mediator of SETDB2 in E2A-PBX1+ leukemia (Figures S5E and S5F). By 
comparison, expression of the CDKN2A gene, which is also subordinate to E2A-PBX1, was 
not dependent on SETDB2 (Figures S6A and S6B), consistent with previous studies of an 
alternative suppressive mechanism involving BMI1 (Smith et al., 2003).
SETDB2 Depletion Enhances Sensitivity to Kinase and Epigenetic Inhibitors
Given the potential roles of targeted therapies in ALL, SETDB2 depletion was evaluated in 
combination with kinase or epigenetic inhibitors for potential therapeutic enhancement. 
Recent preclinical studies have suggested dasatinib, a multi-kinase inhibitor, as a candidate 
therapy in pre-BCR+ ALL (Duque-Afonso et al., 2015, 2016; Geng et al., 2015). Thus, it 
was tested in combination with SETDB2 depletion in RCH-ACV and 697 cells in dose-
response assays. SETDB2 depletion increased dasatinib sensitivity in RCH-ACV and 697 
cells, significantly reducing the half maximal inhibitory concentration (IC50) for dasatinib 
(Figures 6A and 6C). SETDB2 depletion also enhanced sensitivity to JQ1 (Figures 6B and 
6D), a potent inhibitor of the BET family of bromodomain proteins that has broad activity in 
diverse acute leukemia subtypes (Da Costa et al., 2013; Zuber et al., 2011). These data 
suggest that targeting SETDB2 in combination with kinase or epigenetic inhibitors might 
provide improved therapeutic efficacy in E2A-PBX1+ preB-ALL.
DISCUSSION
In this study, we demonstrate an oncogenic role for the protein lysine methyl-transferase 
SETDB2 in leukemia pathogenesis. It is overexpressed in a subset of ALL with the pre-BCR
+
 phenotype and required for their maintenance in vitro and in vivo. In E2A-PBX1+ B-ALL, 
SETDB2 expression is maintained as a direct target gene of the chimeric transcription factor 
E2A-PBX1. In these leukemias, SETDB2 epigenetically suppresses expression of the cell-
cycle inhibitor CDKN2C through histone H3K9 tri-methylation, thereby establishing an 
oncogenic pathway (E2A-PBX1 / SETDB2 / CDKN2C) subordinate to E2A-PBX1 in ALL. 
Our studies provide a strong rationale for the development of pharmacologic inhibitors and 
pre-clinical studies to further establish the efficacy of targeting SETDB2 therapeutically in 
leukemia.
The role of SETDB2 as a transcriptional silencing factor in leukemia is consistent with its 
contributions in various homeostatic processes. These include regulation of early embryonic 
development in zebrafish through epigenetic silencing of target genes (Du et al., 2014; Xu et 
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al., 2010), and association with virus-induced susceptibility to bacteria superinfection by 
suppressing the inflammatory response through epigenetic inhibition of genes in the nuclear 
factor κB (NF-κB) signaling pathway (Schliehe et al., 2015). A potential role in cancer 
pathogenesis has been suggested by genomic sequencing studies (from The Cancer Genome 
Atlas; TCGA) revealing various mutations and copy number alterations of SETDB2 in a 
broad subset of cancers (Figure S4D). However, with the exception of a recent report 
characterizing the role of SETDB2 in a gastric cancer cell line (Nishikawaji et al., 2016), 
there has been no functional link with oncogenesis. Our studies provide this by 
demonstrating that SETDB2 overexpression sustains leukemogenesis based on multiple lines 
of evidence, including mechanistic studies and clinical data.
Through integration of ChIP-seq and transcriptomic datasets, we identified SETDB2 
candidate target genes in E2A-PBX1+ cells based on the criterion that SETDB2 
epigenetically silences subordinate genes by writing the H3K9me3 repressive histone mark. 
The most functionally significant of these target genes is CDKN2C, whose silencing is 
strongly linked to the oncogenic function of SETDB2 in E2A-PBX1+ cells to promote cell-
cycle progression and leukemia cell proliferation. Of note, an additional CDK inhibitor gene 
(CDKN2A) is also silenced in E2A-PBX1+ leukemia cells, but through a different 
mechanism involving BMI1 (Smith et al., 2003). Thus, two distinct oncogenic pathways 
subordinate to E2A-PBX1 mediate silencing of major tumor suppressor genes to promote 
aberrant cell cycling (Figure S6C).
In addition to E2A-PBX1+ ALL, a broad cross-section of other leukemia subtypes, both 
ALL and AML, overexpress SETDB2 and show strong dependence on it for growth and 
proliferation both in vitro and in vivo (data not shown). However, most of these non-E2A-
PBX1 cases do not display upregulation of CDKN2C following SETDB2 knockdown, 
suggesting oncogenic mechanisms based on alternative downstream target genes (data not 
shown). Indeed, the lack of overlap between SETDB2 targets identified in E2A-PBX1+ cells 
and those reported in mouse bone-marrow-derived macrophages (Schliehe et al., 2015), or a 
gastric cancer cell line (Nishikawaji et al., 2016), suggests that SETDB2 downstream targets 
are highly dependent on biological context, but the specific mechanisms for SETDB2 
recruitment to the respective chromatin sites have not been determined. Furthermore, 
although SETDB2 has been shown to methylate substrate H3K9me2 peptide in vitro 
(Falandry et al., 2010), a recent report showed that SETDB2 can positively regulate specific 
targets independent of its H3K9me3 methyltransferase activity (Roqueta-Rivera et al., 
2016). However, this does not appear to apply to the maintenance of leukemias, since several 
of our observations support a requirement for methyltransferase activity including the 
following: (1) H3K9me3 methylation state and expression of the CDKN2C gene were 
reciprocally modulated in parallel by changes in SETDB2 expression, (2) disruption of the 
SET domain by CRISPR caused deleterious effects, and (3) the functional consequences of 
SETDB2 overexpression on leukemia cell maintenance required its SET domain (Figure 
5L). Since we identified SETDB2 targets based on H3K9me3 methylation state change, we 
cannot rule out the possibility that SETDB2 may function on non-histone substrates, like 
other protein lysine methyltransferases, in regulation of ALL leukemogenesis, which merits 
further investigation (Hamamoto et al., 2015; Rathert et al., 2008).
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Overexpression and dependence on SETDB2 provide a rationale for its consideration as a 
therapeutic target for broad subtypes of leukemia, particularly E2A-PBX1+ preB-ALL. By 
comparison, hematopoietic stem cells (HSCs) and progenitors express much lower transcript 
levels than primary leukemias, consistent with their reduced sensitivity to SETDB2 
depletion. The average median expression of SETDB2 in over 50 normal tissues (The 
Genotype-Tissue Expression Project; GTEx) (Figure S4A) is at least 6-fold lower than 
primary AML/ALL samples, suggesting a potential safe therapeutic index. In addition to 
targeting SETDB2 alone, its knockdown enhanced sensitivity to kinase and epigenetic 
inhibitors, suggesting a potential approach to future combination treatments. In conclusion, 
SETDB2 is a functionally important epigenetic regulator in pre-BCR+ ALL that should be 
further investigated as a candidate therapeutic target.
EXPERIMENTAL PROCEDURES
Bioinformatics and Data Analysis
RNA-seq libraries were constructed using Illumina’s TruSeq Stranded mRNA LT Kit and 
sequenced at Centrillion Genomics Technologies (http://www.centrilliontech.com). RAW 
fastq files were mapped by bowtie2 to the human hg19 genome assembly. Mapped (BAM) 
files were subjected to read counting using the R-Bioconductor package 
(GenomicAlignments: summarizeOverlaps function). The expression matrix (prior 
normalization) was then used for differential expression calculations and statistical modeling 
using the R-Bioconductor package (DESeq2). Sample-wise clustering and MA plots were 
generated by the R package “ape” and base function “plotMA.” Protein lysine 
methyltransferase family members were downloaded from the Gene Ontology database 
(amigo.geneontology.org), and heatmaps were generated using R function heatmap.2. 
Primary leukemia expression microarrays were accessed from GEO: GSE13204 (Haferlach 
et al., 2010). Raw microarray image processing, expression calling, and normalization were 
performed by the R-Bioconductor package “affy.” ChIP-seq samples were analyzed as 
follows: (1) Reads mapped by BWA to human genome assembly hg19; (2) peaks were called 
and differential peaks were analyzed using MAC2; (3) peaks were viewed by the genome 
browser integrative genomics viewer (IGV); and (4) density plots and heatmaps were 
generated using the program ngsplot. Normalized SETDB2 expression values (RPKM) of 
hematopoietic cells (HSCs, common myeloid progenitors [CMPs], and common lymphoid 
progenitors [CLPs]) and AML primary samples were downloaded from TCGA (https://tcga-
data.nci.nih.gov/) and Blueprint (http://dcc.blueprint-epigenome.eu/#/home). Normal tissue 
expression was accessed from GTEx (https://www.gtexportal.org).
ChIP and Genomic qPCR
ChIP assays were performed as described elsewhere (Duque-Afonso et al., 2016). Briefly, 
cells were harvested and fixed with 1% fresh formaldehyde, and immune-complexes were 
precipitated using anti-SETDB2 (M17, Abnova) or anti-H3K9me3 antibody (ab8898, 
Abcam) with Protein G Dynabeads (10003D, Invitrogen) or GFP-Trap magnetic beads 
(gtma-20 and bmab-30, ChromoTek). Real-time qPCR was performed on the precipitated 
DNA using primers flanking the SETDB2, CDKN2C, IGLL1, IgH Eu, and NCAPD2 genes. 
Previously published ChIP-seq peaks for E2A-PBX1 were chosen for validation as controls 
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(Geng et al., 2015). The relative values to input were determined using SYBR Green. 
Primers are listed in Table S1.
Real-Time qPCR
RNA was isolated using TRIzol Reagent, and cDNA was synthesized using iScript Reverse 
Transcription Supermix (Bio-Rad) following the manufacturer’s recommendations. qPCR 
analysis was performed using a CFX384 real-time PCR system (Bio-Rad) with TaqMan 
Master Mix and primers (Applied Biosystems). All signals were quantified using the ΔCt 
method and were normalized to the level of Actb. TaqMan probes used in real-time PCR are 
provided in Table S2.
Cell Culture
293T and Phoenix cells were cultured in DMEM supplemented with 10% fetal bovine serum 
(FBS), 100 U/mL penicillin/streptomycin, and 0.29 mg/mL L-glutamine. Human leukemia 
cell lines were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 U/mL 
penicillin/streptomycin, and 0.29 mg/mL L-glutamine. HSPCs were isolated from fresh 
human umbilical cord blood or bone marrow obtained from the Stanford Hospital using 
Ficoll-Paque Plus (GE Healthcare Life Sciences), followed by the EasySep Human CD34+ 
Selection or Progenitor Enrichment Kit (STEMCELL Technologies) to obtain enrichment 
>90%. Following isolation, cells were maintained in serum-free StemSpan II media 
(STEMCELL Technologies) supplemented with cytokines (PeproTech: stem cell factor 
[SCF], thrombopoietin [TPO], Flt3L, interleukin [IL]-6, IL-3 [100 ng/mL each]; Cellagen 
Technology: StemRegenin1 [SR1; 0.75 μM]) (Buechele et al., 2015).
shRNA Design, Lentivirus Generation, and Cell Transduction
shRNAs were designed using a commercial web tool (Invitrogen). Individual shRNA 
sequences (Table S3) were cloned into a p309-mCherry, p309-GFP (Bassik et al., 2013; 
Matheny et al., 2013), or pSicoR-mCherry (Ventura et al., 2004) lentiviral vector. Lentivirus 
generation and transduction of human leukemia cells are described elsewhere (Wong et al., 
2015). The sorted mCherry+ cells were cultured for 7 days for colony-forming assay or used 
in bone marrow transplantation experiments.
Expression Vector Construction and Retrovirus Preparation
E2A-PBX1, SETDB2, and CDKN2C cDNAs fused with GFP were generated by the In-
Fusion cloning system (Clontech Laboratories) and cloned into pMSCV-puro vector 
(Clontech). SETDB2 cDNA was obtained from GE Healthcare Life Sciences (clone 
MHS6278-202808172). Retrovirus generation and transduction of human leukemia cells are 
described elsewhere (Wong et al., 2015). Briefly, retrovirus was packaged in Phoenix-Eco 
cells, and RCH-ACV cells expressing ecotropic receptor were used for transduction by 
spinoculation (2,500 rpm, 32°C, for 2.5 hr). GFP+ cells were sorted by FACS 3 days after 
transduction.
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sgRNA Construction and Validation
The pL-CRISPR.EFS.GFP lentiviral vector (#57818, Addgene) was used for the 
construction of sgRNA expression vectors (Heckl et al., 2014). sgRNA sequences targeting 
the SET1 or SET2 domain of SETDB2 were selected from the Gecko v2 database and listed 
in Table S4. GFP+ cells were sorted and mixed 50/50 with untransduced cells for cell 
proliferation assay. Indel frequency was analyzed by Sanger sequencing and T7 
endonuclease assay using primers listed in Table S5.
Colony-Forming Assays
Human leukemia cells, cord blood CD34+ cells, or adult bone marrow CD34+ cells 
(obtained with informed consent and Stanford University Institutional Review Board 
approval) were transduced with shRNAs against the gene of interest or luciferase (control), 
followed by cell sorting after 4 days. mCherry+ human leukemia cells (2,000 cells per well) 
were cultured in methylcellulose medium (H4230, STEMCELL Techonologies). Colonies 
were counted after 7 days. mCherry+ cord blood CD34+ cells or adult bone marrow CD34+ 
cells (10,000 cells per well) were cultured in Methocult H4230 methylcellulose medium 
(STEMCELL Technologies) supplemented with SCF, TPO, Flt3L, IL-6, IL-3 (100 ng/mL 
each), and SR1 (0.75 mM) (Buechele et al., 2015). Colonies were counted after 10 days.
Transplantation Assays
Transplantation assays were performed as previously described (Wong et al., 2015). RCH-
ACV human leukemia cells were transduced with control (shLuc) or SETDB2 (shSETDB2) 
shRNA lentivirus with mCherry fluorescence reporter by spinoculation. After 72 hr, sorted 
mCherry+ cells in 0.2 mL PBS containing 0.5% FBS were transplanted into sublethally 
irradiated (200 rad) NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (8–10 weeks old). All 
experiments on mice in this study were performed with the approval of, and in accordance 
with, the Stanford University Panel on Laboratory Animal Care.
Cell-Cycle Analysis
Bromodeoxyuridine (BrdU)/7-AAD incorporation assays were performed according to the 
manufacturer’s protocol (#559619, BD Pharmingen). BrdU incorporation (APC 
[allophycocyanin]- or FITC [fluorescein isothiocyanate]-labeled anti-BrdU antibodies) was 
measured with DNA content (7-ADD) in fixed and permeabilized cells.
Western Blot Analysis
Acid-extracted nuclear protein fractions were used for western blots to detect histone 
modifications (Wong et al., 2015). The blots were reacted with primary antibodies specific 
to histone H3 (ab1791, Abcam), histone H3K9me3 (ab8898, Abcam), GAPDH (G9545, 
Sigma-Aldrich), α-tubulin (A01410-40, GenScript), S-Tag (A190-135A, Bethyl 
Laboratories), SETDB2 (M17, Abnova), or E2A (3C6, monoclonal antibody specific for 
E2A) (Jacobs et al., 1993), followed by peroxidase-conjugated secondary antibodies. 
Membranes were then incubated with ECL Western Blot Detection kits (GE Healthcare), 
and images were detected by exposure to X-ray film.
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Luciferase Reporter Assay
The Dual Luciferase Reporter Assay system (Promega) was used according to the user’s 
manual. Promoter regions of NCAPD2, SETDB2, and immunoglobulin H (IgH) Eu were 
cloned into pGL3-basic vector, a Firefly luciferase reporter vector, using primers listed in 
Table S6. The reporter constructs and E2A-PBX1 expression vector, together with the pRL-
SV40 vector, a Renilla luciferase control reporter vector, were transfected into 293T cells. 
Cells were harvested 48 hr after transfection and lysed with passive lysis buffer (Promega). 
Luciferase activity was measured with the Glomax 20/20 Luminometer (Promega) and 
normalized to Renilla luciferase activity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• SETDB2 is overexpressed in pre-BCR+ acute lymphoblastic leukemias
• SETDB2 is a direct target gene of the E2A-PBX1 chimeric oncoprotein
• SETDB2 mediates chromatin suppression of CDKN2C in E2A-PBX1+ ALL
• Depletion of SETDB2 sensitizes ALL cells to kinase and epigenetic inhibitors
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Figure 1. SETDB2 Is a Direct Target Gene of E2A-PBX1 in Pre-BCR+ Leukemia
(A) Heatmap shows expression levels of protein lysine methyltransferase (PKMT) family 
proteins in the indicated cell lines with or without E2A-PBX1 knockdown. Normalized 
expression level is expressed as log2 of FPMK (fragments per million read per thousand 
gene length). Heatmap of log2 fold changes is calculated from comparing the fold change of 
mean expression value in E2A-PBX1-depleted cells (KD) versus control cells (Ctr). Rows 
that include green blocks indicate genes downregulated in E2A-PBX1-depleted cells.
(B) Western blot analysis shows the expression of SETDB2 after E2A-PBX1 knockdown in 
RCH-ACV and 697 cell lines. GAPDH was used as loading control.
(C) Boxplot of SETDB2 expression level distribution in primary E2A-PBX1 B-ALL 
samples versus mononuclear cells of healthy donors. Notches are displayed in the boxplot to 
indicate significant median difference at 95% confidence if two notches do not overlap. 
Sample mean is indicated as a red dot within boxplot. Significant mean difference is 
calculated by unpaired t test; *p < 0.0002.
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(D) Bar graph indicates chromatin occupancy determined by ChIP-qPCR of exogenous 
E2A-PBX1 GFP-fusion protein in RCH-ACV cells. IgH Eu and NCAPD2 served as positive 
and negative controls, respectively. Data indicate mean ± SEM (n = 3). Statistical analysis 
was performed by Student t test. *p < 0.05; n.s., not significant; TSS, transcription start site.
See also Figures S1 and S2.
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Figure 2. Dependency of Human E2A-PBX1+ Leukemia Cells on SETDB2 for Growth and 
Maintenance
(A) E2A-PBX1+ cell lines were transduced with lentiviral vectors expressing control 
(shLuc) or SETDB2 shRNAs. mCherry positive cells were sorted and relative SETDB2 
transcript levels were quantified by qRT-PCR 4 days after transduction.**p < 0.01; ***p < 
0.001.
(B) Western blot analysis indicates shRNA-mediated knockdown of SETDB2 in E2A-
PBX1+ cell lines. GAPDH was used as loading control.
(C and D) Cell proliferation and colony-forming assays of human E2A-PBX1+ cell lines 
after shRNA-mediated knockdown of SETDB2. Cell numbers (C) and colony numbers (D) 
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were enumerated after 4 and 5 days, respectively, and expressed relative to the numbers 
obtained with control shRNA-transduced cells. Data indicate means ± SEM (n = 3). **p < 
0.01; ***p < 0.001.
(E) Representative colony morphologies are shown for the experiment in (C). Scale bars, 
400 μm.
(F) Survival curves are shown for a cohort of mice transplanted with RCH-ACV leukemia 
cells treated with control or SETDB2 shRNAs in two cell dosages, 5 × 104 and 4 × 106 (n = 
7 in each cohort). Log-rank test was used for statistical analysis.
(G) SETDB2 transcript levels are shown for bone marrow cells isolated from diseased mice 
10 and 20 days after transplantation with control or SETDB2 shRNAs, respectively. Data 
indicate means ± SEM (n = 3). n.s., not significant.
(H) Scheme is indicated for SETDB2 sgRNAs. MBD, methyl-CpG binding domain; Pre, 
pre-SET motif; SET, SET domain.
(I) Gel image shows the result of T7 endonuclease assay performed on genomic DNA 
isolated from RCH-ACV cells transduced with 3 different SETDB2 sgRNAs. Digested PCR 
products (indicated by red asterisks) of the SETDB2 locus represent the presence of strand 
mismatches resulting from indels that were generated from imprecise repair of a DNA 
double-strand break.
(J) RCH-ACV cells were transduced with Cas9 vector only or together with SETDB2 
sgRNAs, and GFP+ cells were sorted after 4 days. GFP+ cells were mixed 50/50 with non-
treated RCH-ACV cells and monitored every 2 days. Diagram indicates mean ± SEM (n = 
3).
See also Figure S3.
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Figure 3. Depletion of SETDB2 Minimally Impacts Normal HSPCs
(A) Boxplot shows the relative expression level of SETDB2 in normal cord blood CD34+ 
cells (CB CD34+; n = 3), adult bone marrow CD34+ cells (adult BM CD34+; n = 3), ALL 
patients (n = 6), and AML patients (n = 4).
(B) Boxplot shows SETDB2 expression (RNA-seq) in normal human and mouse HSCs and 
progenitors and various subtypes of acute leukemia (RNA-seq data from the European 
Blueprint database).
(C–E) Normal cord blood CD34+ cells and (F–H) adult bone marrow CD34+ cells were 
transduced with lentiviral vectors expressing control (against luciferase, shLuc) or SETDB2 
shRNAs. mCherry-positive cells were sorted, and relative SETDB2 transcript level was 
quantified by qRT-PCR 4 days after transduction (C and F). Colony-forming assays of 
human cord blood and bone marrow CD34+ cells after shRNA-mediated knockdown of 
SETDB2 were performed. Colony numbers (D and G) were enumerated after 10 days and 
expressed relative to the numbers obtained with control shRNA-transduced cells. Data 
indicate mean ± SEM (n = 3). **p < 0.01; ***p < 0.001. Representative colony 
morphologies are also shown (E and H).
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(F–H) Same experiments as in (C)–(E) were performed, using adult bone marrow CD34+ 
cells. n.s., not significant.
Scale bars, 400 μm.
See also Figure S4.
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Figure 4. Cell-Cycle-Related Genes Are Potential SETDB2 Downstream Targets
(A) Western blot shows H3K9me3 levels in the indicated cells before and after SETDB2 
knockdown.
(B and C) H3K9me3 levels as shown for genome-wide H3K9me3 ChIP-seq on SETDB2 
knockdown or control cells. Number of mapped reads (B) and density heat map (C) are 
shown.
(D) GSEA plots are shown for indicated gene sets in SETDB2 knockdown versus control 
cells.
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(E) H3K9me3 ChIP-seq profiles of a subset of potential SETDB2 target genes (n = 27) are 
shown for SETDB2 knockdown and control cells.
(F) Schematic illustration shows ChIP-seq peaks in CDKN2C locus.
See also Figure S5.
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Figure 5. Oncogenic Mechanism for SETDB2 Role in Human Leukemia
(A) Bar graph shows chromatin occupancy determined by ChIP-qPCR of endogenous 
SETDB2 in RCH-ACV and 697 cells.
(B and C) Bar graph shows H3K9me3 level determined by ChIP-qPCR after SETDB2 
knockdown (B) or overexpression of exogeneous SETDB2 GFP-fusion protein (C) in RCH-
ACV cells.
(D) Bar graph shows chromatin occupancy determined by ChIP-qPCR of exogenous 
SETDB2 GFP-fusion protein in RCH-ACV cells. NCAPD2 served as negative control.
(E and F) Bar graphs indicate CDKN2C expression levels in RCH-ACV and 697 cells after 
E2A-PBX1 (E) or SETDB2 (F) shRNA treatment.
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(G and H) Flow cytometry plot (G) and bar graph (H) show results of BrdU/7-AAD staining 
to assess cell-cycle status by flow cytometry in RCH-ACV cells after SETDB2 or CDKN2C 
knockdown.
(I and J) Flow cytometry plot (I) and bar graph (J) show results of cell-cycle analysis for 
CDKN2C overexpression in RCH-ACV cells.
(K) Bar graph shows RCH-ACV cell proliferation status after exogenous SETDB2 or 
CDKN2C overexpression.
(L) Bar graph shows RCH-ACV proliferation status after overexpression of exogenous 
SETDB2 WT or SET domain deletion mutants. Data indicate mean ± SEM (n = 3). 
Statistical analysis was performed by Student t test. *p < 0.05; **p < 0.01; ***p < 0.001; 
n.s., not significant.
See also Figures S5 and S6.
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Figure 6. SETDB2 Knockdown Increases Sensitivity to Kinase and Epigenetic Inhibitors
(A and C) Dose-response curves are shown for control or SETDB2 shRNA-treated RCH-
ACV (A) and 697 (C) cells cultured in increasing concentrations of dasatinib. IC50 for 
dasatinib in combination with control or SETDB2 shRNA is 24.84 versus 9.23 nM (for 
RCH-ACV cells) and 560 versus 154 nM (for 697 cells), respectively.
(B and D) Dose-response curves are shown for control or SETDB2 shRNA-treated RCH-
ACV (B) and 697 (D) cells cultured in increasing concentrations of JQ1. IC50 for JQ1 in 
combination with control or SETDB2 shRNA is 172.6 versus 112.5 nM (for RCH-ACV 
cells) and 316.4 versus 192.8 nM (for 697 cells), respectively.
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